GlassScriptPhysician profile
Barbara Adamiak
NPI 1013261429
$9,354.85
in general payments reported to CMS, 2019-2025
58 companies · $4,456 in 2025
The $4,456 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $223 · 2023: $334 · 2024: $3,531 · 2025: $4,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,236 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,235.77 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $660.34 | 2024-2025 | |
| Pfizer INC. | $644.13 | 2024-2025 | |
| Janssen Biotech, INC. | $588.58 | 2021-2025 | Rybrevant, Erleada, Carvykti |
| Incyte Corporation | $512.62 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $450.45 | 2021-2025 | Vyloy, Padcev, Xospata |
| Astrazeneca Pharmaceuticals LP | $443.61 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $443.22 | 2021-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $408.21 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $337.95 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Abbvie INC. | $324.38 | 2021-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $305.71 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $294.05 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $279.08 | 2021-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $248.73 | 2021-2025 | Tecentriq, Polivy, Alecensa |
| Bayer Healthcare Pharmaceuticals INC. | $245.27 | 2024-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $219.34 | 2021-2025 | |
| Lilly USA, LLC | $187.29 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $181.24 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Glaxosmithkline, LLC. | $156.57 | 2024-2025 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $143.49 | 2024-2025 | Libtayo |
| Taiho Oncology, INC. | $131.53 | 2024-2025 | |
| Beone Medicines USA, INC. | $123.46 | 2025 | Brukinsa |
| Beigene USA, INC. | $115.21 | 2021-2024 | Brukinsa |
| Eisai INC. | $111.35 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $110.60 | 2024-2025 | Monoferric, Cosela |
| Kyowa Kirin, INC. | $99.46 | 2024-2025 | Poteligeo |
| Sobi, INC | $99.32 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $98.01 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $94.93 | 2024-2025 | Ultomiris |
| Tersera Therapeutics LLC | $88.49 | 2023-2025 | Zoladex |
| Genzyme Corporation | $85.05 | 2022-2025 | |
| Blueprint Medicines Corporation | $79.52 | 2024-2025 | Ayvakit |
| Stemline Therapeutics INC. | $77.99 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $69.31 | 2024-2025 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $66.17 | 2025 | Onivyde |
| Pharmaessentia USA Corporation | $64.00 | 2024-2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $62.09 | 2023-2025 | Fotivda |
| Puma Biotechnology, INC. | $60.09 | 2024-2025 | |
| Seagen INC. | $59.50 | 2021-2023 | Tukysa |
| Emd Serono, INC. | $58.74 | 2024-2025 | |
| Kite Pharma, INC. | $54.79 | 2021-2025 | Yescarta |
| Servier Pharmaceuticals LLC | $50.81 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $46.51 | 2025 | Clonoseq |
| Novocure INC. | $43.67 | 2025 | Optune Lua (Novottf-200t) |
| Amgen INC. | $40.82 | 2021 | |
| Recordati_rare_diseases_inc. | $38.53 | 2024-2025 | Enjaymo, Sylvant |
| Karyopharm Therapeutics INC. | $38.22 | 2021-2024 | Xpovio |
| Springworks Therapeutics, INC. | $23.67 | 2024 | Ogsiveo |
| Pharmacyclics LLC, An Abbvie Company | $22.79 | 2021 | |
| Genmab U.S., INC. | $22.52 | 2024 | Epkinly |
| Sanofi-Aventis U.S. LLC | $22.07 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.20 | 2025 | Givlaari |
| Agios Pharmaceuticals, INC. | $21.09 | 2025 | Pyrukynd |
| Cumberland Pharmaceuticals, INC. | $18.32 | 2024 | Sancuso |
| Legend Biotech USA INC. | $16.02 | 2024 | |
| Apellis Pharmaceuticals, INC. | $15.47 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.76 | 2024 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $14.51 | 2025 | Qinlock, Romvimza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Adamiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.